Literature DB >> 23000337

Haploidentical hematopoietic stem cell transplantation for lymphoma with monosomy of chromosome 6 (loss of heterozygosity in the HLA region)--who should be a donor?

Kazuhiro Ikegame1, Katsuji Kaida, Leif Lakoma, Shinichi Ishii, Takayuki Inoue, Ruri Kato, Toshihiro Soma, Masaya Okada, Hiroyasu Ogawa.   

Abstract

Hematopoietic stem cell transplantation (HSCT) from an HLA haploidentical family donor is an option for patients who do not have a full HLA matched donor and lack the time to find an unrelated one [1,2]. Furthermore, it may facilitate a powerful graft versus leukemia/lymphoma (GVL) effect to help combat hematological malignancies by directly targeting the mismatched HLA expressed on leukemia/lymphoma cells [3]. On the contrary, leukemia/lymphoma cells escape from the surveillance of the donor-derived GVL effect by losing the target HLA (mismatched HLA in GVH direction). This mechanism has been called loss of heterozygosity (LOH) in the HLA gene region on chromosome 6 [4,5]. Taking the above into account, in this case report, we present a case of lymphoma with monosomy 6, which means natural LOH of HLA, and suggest that selection of a haploidentical family donor matched with the missing HLA haplotype seems to be very effective.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23000337     DOI: 10.1016/j.trim.2012.09.002

Source DB:  PubMed          Journal:  Transpl Immunol        ISSN: 0966-3274            Impact factor:   1.708


  1 in total

1.  Combination of Complement-Dependent Cytotoxicity and Relative Fluorescent Quantification of HLA Length Polymorphisms Facilitates the Detection of a Loss of Heterozygosity.

Authors:  Klaus Witter; Roland Reibke; Marion Subklewe; Robert Zahn; Teresa Kauke; Karsten Spiekermann; Michael Spannagl; Johanna Tischer; Wolfgang Hiddemann; Andrea Dick
Journal:  Bone Marrow Res       Date:  2014-04-03
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.